RMEA Stock Overview
Develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
No risks detected for RMEA from our risk checks.
My Notes
Capture your thoughts, links and company narrative
ResMed Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.60 |
| 52 Week High | US$23.60 |
| 52 Week Low | US$14.90 |
| Beta | 0.68 |
| 1 Month Change | -5.26% |
| 3 Month Change | 0% |
| 1 Year Change | 38.46% |
| 3 Year Change | -5.26% |
| 5 Year Change | 58.82% |
| Change since IPO | 552.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| RMEA | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.4% | -2.9% | -2.6% |
| 1Y | 38.5% | -8.5% | 6.9% |
Return vs Industry: RMEA exceeded the German Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: RMEA exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| RMEA volatility | |
|---|---|
| RMEA Average Weekly Movement | 3.5% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RMEA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: RMEA's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 9,980 | Mick Farrell | www.resmed.com |
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.
ResMed Inc. Fundamentals Summary
| RMEA fundamental statistics | |
|---|---|
| Market cap | €33.37b |
| Earnings (TTM) | €1.07b |
| Revenue (TTM) | €4.61b |
31.3x
P/E Ratio7.2x
P/S RatioIs RMEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RMEA income statement (TTM) | |
|---|---|
| Revenue | US$4.81b |
| Cost of Revenue | US$2.00b |
| Gross Profit | US$2.80b |
| Other Expenses | US$1.69b |
| Earnings | US$1.11b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.58 |
| Gross Margin | 58.33% |
| Net Profit Margin | 23.15% |
| Debt/Equity Ratio | 13.0% |
How did RMEA perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield26%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 10:20 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ResMed Inc. is covered by 56 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | ANZ Equities Pty Limited |
| Russell Wright | APP Securities Pty Ltd. |
| David Rescott | Baird |